HOME >> BIOLOGY >> NEWS
Jefferson scientists use gene therapy to reverse heart failure in animals

(PHILADELPHIA) Heart researchers at the Center for Translational Medicine at Jefferson Medical College have used gene therapy to reverse heart failure in animals. In addition, they found that this gene therapy strategy had "unique and additive effects" to currently used, standard heart failure drugs called beta-blockers.

Reporting in the American Heart Association journal Circulation, researchers led by Walter J. Koch, Ph.D., director of the Center for Translational Medicine and the George Zallie and Family Laboratory for Cardiovascular Gene Therapy in the Department of Medicine at Jefferson Medical College of Thomas Jefferson University in Philadelphia, used a virus to carry the gene for a protein, S100A1, into the heart cells of rats with heart failure. The virus expressed the S100A1 gene only in heart cells and not in other organs, essentially making it a tailored therapy. After 18 weeks, those animals that received the gene therapy had significantly improved heart function compared to animals that did not receive the treatment.

Specifically, the Koch team, including Patrick Most, M.D., and Joseph Rabinowitz, Ph.D., also in Jefferson's Center for Translational Medicine, experimentally produced heart failure in the animals, which is characterized by a dramatic reduction in the heart's pumping ability. The scientists then delivered a modified adeno-associated virus (AAV) that contained the S100A1 gene to the heart's coronary arteries with the help of a novel heart-specific "gene promoter" that enabled the gene to be present only in heart cells.

The rats with heart failure were then followed for another two months, when their heart pumping function was monitored again. The animals that received the gene therapy had significantly better heart-pumping abilities compared to the pre-gene therapy level, and overall, the S100A1-treated rats had improved heart health. The researchers found this in both individual heart cells and in the whole
'"/>

Contact: Steve Benowitz
steven.benowitz@jefferson.edu
215-955-5291
Thomas Jefferson University
23-May-2007


Page: 1 2 3

Related biology news :

1. Jefferson scientists patent dramatically improves
2. Marker predicts pancreatic cancer outcome after surgery, Jefferson surgeon finds
3. Tiny genes may increase cancer susceptibility, Jefferson scientists find
4. Jefferson researchers discovery may change thinking on how viruses invade the brain
5. Jefferson scientists identify protein key to breast cancer spread, potential new drug target
6. Jefferson scientists find rabies-based vaccine could be effective against HIV
7. Jefferson scientists uncover gene mutation that cuts colon polyps, may suppress cancer
8. Targeting the adrenal gland could be key strategy against heart failure, Jefferson scientists show
9. Jefferson scientists find guardian genes choices crucial to stopping cancer process
10. Jefferson researchers uncover new way nature turns genes on and off
11. Jefferson researchers develop combined procedure for uterine preservation in treating fibroids

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/13/2020)... ... June 11, 2020 , ... ... a significant expansion of its forensic genealogy team. Bode’s Forensic Genealogy Service ... proven forensic genealogy and DNA analysis methods. The team has added experienced genealogists, ...
(Date:6/5/2020)... ... ... Greffex, a pioneering vaccine and gene therapy company based in Houston, Texas, ... for a global perspective to make an impact in a post pandemic world,” said ... an independent, director of the company. , “The Greffex board is excited to have ...
(Date:5/28/2020)... Del. (PRWEB) , ... May ... ... Biosciences (DuPont) has announced a new enzyme solution for adjunct liquefaction: AMYLEX® ... alike including the ability to expand into new segments with locally-sourced raw ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a ... of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. ... lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine ...
(Date:7/1/2020)... GREEN, Ohio (PRWEB) , ... June 29, 2020 ... ... that offers access to competitively procured purchasing contracts to its membership, recently named ... to provide TIPS members with the opportunity to purchase ergonomic seating, cafeteria tables, ...
(Date:6/28/2020)... Conn. (PRWEB) , ... June 25, 2020 , ... ... formed to advance photodynamic therapy for treating cancer, today announced the company has ... York (“Roswell Park”). The agreement provides Lumeda globally exclusive rights to Roswell ...
(Date:6/23/2020)... ... June 22, 2020 , ... Regen Suppliers, the one ... includes buy three, get the fourth unit free with no limit on the ... known as exosomes, have been a game changer for regenerative therapies. The products ...
Breaking Biology Technology:
Cached News: